0.8971 -0.023 (-2.45%) | 03-28 12:51 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1.14 | 1-year : | 1.22 |
Resists | First : | 0.97 | Second : | 1.04 |
Pivot price | 0.9 | |||
Supports | First : | 0.86 | Second : | 0.71 |
MAs | MA(5) : | 0.9 | MA(20) : | 0.91 |
MA(100) : | 1.02 | MA(250) : | 2.09 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 38.2 | D(3) : | 33.6 |
RSI | RSI(14): 43.4 | |||
52-week | High : | 4.34 | Low : | 0.72 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NAOV ] has closed above bottom band by 41.9%. Bollinger Bands are 84% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.95 - 0.96 | 0.96 - 0.96 |
Low: | 0.87 - 0.87 | 0.87 - 0.88 |
Close: | 0.93 - 0.93 | 0.93 - 0.94 |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
Thu, 28 Mar 2024
NanoVibronix signs agreement with Veranex (NASDAQ:NAOV) - Seeking Alpha
Tue, 26 Mar 2024
NAOV Stock Quote Price and Forecast - CNN
Thu, 21 Mar 2024
NANO VIBRONIX INC. Trade Ideas — SWB:56R0 — TradingView - TradingView
Sat, 16 Mar 2024
NanoVibronix, Inc. (NASDAQ:NAOV) Sees Large Decline in Short Interest - Defense World
Tue, 13 Feb 2024
Premarket Mover: NanoVibronix Inc (NAOV) Up 4.07% - InvestorsObserver
Wed, 06 Dec 2023
NanoVibronix Featured in Your Bladder Health Magazine - Business Wire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 2 (M) |
Shares Float | 2 (M) |
Held by Insiders | 0.5 (%) |
Held by Institutions | 16.3 (%) |
Shares Short | 10 (K) |
Shares Short P.Month | 5 (K) |
EPS | -3.16 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 2.54 |
Profit Margin | 0 % |
Operating Margin | -146.3 % |
Return on Assets (ttm) | -41.7 % |
Return on Equity (ttm) | -126.4 % |
Qtrly Rev. Growth | 372.2 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0.48 |
EBITDA (p.s.) | -2.04 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -4 (M) |
Levered Free Cash Flow | -2 (M) |
PE Ratio | -0.29 |
PEG Ratio | 0 |
Price to Book value | 0.35 |
Price to Sales | 1.83 |
Price to Cash Flow | -0.42 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |